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Abstract Alzheimer’s disease (AD) is characterised by a
progressive loss of cognitive functions. Histopathologi-
cally, AD is defined by the presence of extracellular
amyloid plaques containing Ab and intracellular neurofib-
rillary tangles composed of hyperphosphorylated tau pro-
teins. According to the now well-accepted amyloid cascade
hypothesis is the Ab pathology the primary driving force of
AD pathogenesis, which then induces changes in tau pro-
tein leading to a neurodegenerative cascade during the
progression of disease. Since many earlier drug trials
aiming at preventing Ab pathology failed to demonstrate
efficacy, tau and microtubules have come into focus as
prominent downstream targets. The article aims to develop
the current concept of the involvement of tau in the neu-
rodegenerative triad of synaptic loss, cell death and den-
dritic simplification. The function of tau as a microtubule-
associated protein and versatile interaction partner will
then be introduced and the rationale and progress of current
tau-directed therapy will be discussed in the biological
context.
Key Points
Oligomeric, soluble Ab exerts toxic effects, which
are at least partially mediated through tau protein by
inducing the neurodegenerative triad of synapse loss,
dendritic simplification and cell death in Alzheimer’s
disease.
Decreasing tau aggregation or lowering the level of
potentially toxic tau species may be a promising
therapeutic approach.
Most drugs that are currently in clinical trials do not
qualify as primarily tau-targeting agents since they
have pleiotropic actions and evidence that they
exhibit their main biological function on tau is weak.
1 Pathophysiology of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common neurode-
generative disorder and is clinically defined by a progres-
sive loss of cognitive functions, resulting in severe
dementia [1]. More than 95 % of AD cases are late-onset
with the greatest risk factor being the advanced age. Other
risk factors include the apolipoprotein e4 allele [2, 3],
cardiovascular disease risk factors [4, 5], inflammation [6]
and traumatic brain injury [7].
Histopathologically, AD is characterised by the presence
of extracellular amyloid plaques containing the aggregated
amyloid precursor protein (APP) peptide fragment Ab and
intracellular neurofibrillary tangles (NFTs) composed of
hyperphosphorylated tau proteins in paired helical or
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straight filaments (PHFs, SFs) [8]. The brains of patients
with advanced AD show dramatic shrinkage due to
extensive cell loss. However, it has become evident that
changes in the brain may begin 20 or more years before
cognitive symptoms appear and these involve loss of
synaptic contacts and changes in neuronal morphology [9,
10]. With respect to tau pathology, NFT formation spreads
to various brain areas following a stereotyped pattern of six
neuropathological stages [11]. In the first two stages,
patients are cognitively unimpaired.
Microscopic analysis of brains from AD patients and
various animal models has revealed a neurodegenerative
triad of cellular changes, which accompany the
development of the disease. The neurodegenerative triad
consists of (1) a decrease in the density and changes in the
shape of dendritic spines, which represent the postsynaptic
site of most excitatory input in neurons [12, 13], (2) a loss
of neurons in selected brain regions [14], and (3) dendritic
simplification in a subset of neurons [15] (Fig. 1).
For the development of mechanism-based therapies, an
understanding of the relation between the histopathological
abnormalities and the neurodegenerative triad is essential.
The so-called ‘amyloid cascade hypothesis’ has become
the focus of a great deal of AD research and is strongly
supported by the observation that familial forms of AD
(FAD) (which represent less than 5 % of all AD cases) are
Fig. 1 The modified amyloid cascade hypothesis and the neurode-
generative triad in Alzheimer’s disease. The schematic indicates how
oligomeric Ab induces the neurodegenerative triad of synaptic
changes, dendritic simplification and neuron loss via tau-dependent
and -independent mechanisms. Sites of potential therapeutic inter-
ventions against tau pathology are indicated in blue colour. See text
for detail. GSK3b glycogen synthase kinase 3b
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associated with an increased formation of Ab [16]. The
original amyloid hypothesis postulated that accumulation
of Ab in the brain is the primary influence driving AD
pathogenesis. However, analysis of the distribution of the
histopathological lesions has shown that tau inclusions
correlate much better with cognitive impairment than
amyloid plaques [17]. Cell studies and animal experiments
confirmed that oligomeric, soluble Ab rather than insoluble
amyloid plaques exert the toxic effect and that the neu-
rodegenerative changes are mediated at least partially
through changes in tau protein via transmembrane sig-
nalling (Fig. 1) [13, 18–22].
Thus, according to the modified amyloid cascade
hypothesis, soluble oligomeric assemblies of Ab induce the
neurodegenerative triad [23]. Ab leads to the activation of
the calcium-dependent phosphatase calcineurin (PP2B)
through N-methyl-D-aspartate (NMDA) glutamate receptor
(NMDAR) activation [19, 24–27], but also calcium flux-
independent NMDAR signalling has been reported [28]. In
addition, elevated calcium levels caused by activation of
metabotropic glutamate receptor 5 [29–31] or L-type
voltage-gated calcium channels [32, 33] have been
observed. Despite the general involvement of calcineurin,
the downstream events appear mechanistically distinct
(Fig. 1, lower part). The presence of oligomeric Ab suf-
fices to induce a loss of dendritic spines and a shift of spine
morphology from mushroom to stubby, while the death of
neurons involves the combined action of Ab and tau [24].
Tau-mediated cell death requires increased phosphoryla-
tion (hyperphosphorylation) of tau and activation of
glycogen synthase kinase 3b (GSK3b). A soluble, hyper-
phosphorylation-mimicking tau construct induced cell
death per se indicating that tau hyperphosphorylation is the
determining factor in Ab-induced cell death, that tau-tox-
icity does not require the formation of higher order tau
aggregates (such as PHFs or NFTs) and that hyperphos-
phorylated tau kills neurons by a ‘toxic gain of function’
mechanism [24, 34–36]. The mechanisms, which are
involved in mediating dendritic simplification, are much
less understood, although dendritic changes have long been
recognised in AD. Very recent data employing an ex vivo
model of tau and Ab-mediated degeneration indicate that
also dendritic simplification is mechanistically distinct
from the other two aspects of the neurodegenerative triad
and involves dysregulation of microtubule dynamics by
dendritic tau, which becomes dephosphorylated at specific
sites [37]. It is noteworthy that the three aspects of the
neurodegenerative triad are also distinct with respect to
their region specificity; dendritic simplification is restricted
to principal neurons of the CA1 region of the hippocampus
[37, 38], while neuron loss occurs mainly in the CA3
region [24]. Spine changes are more widespread in the
hippocampus.
AD-related neuronal changes develop over years and the
different aspects of the neurodegenerative triad may
emerge at different time points. Results from animal
models and organotypic cultures indicate that synaptic
changes and loss of dendritic spines occur very early dur-
ing disease progression [39] and are reversible by restoring
the cAMP/PKA/CREB signalling pathway or decreasing
the amount of Ab [19, 40]. Dendritic simplification and
neuron loss appear to develop later during disease, sug-
gesting that the tau-dependent aspects of the neurodegen-
erative triad are characteristic for the further progression of
AD. It is obvious that neuron loss is not reversible, while it
is unclear whether dendritic simplification can be reversed.
It should also be noted that synaptic loss and dendritic
simplification are mediated by disturbance of the
cytoskeleton raising the possibility that drugs, which
modulate cytoskeletal dynamics, in particular the dynam-
icity of the microtubule network, could be of therapeutic
use to counteract changes, which are mediated by tau-de-
pendent or -independent mechanisms (see below).
Originally the search for therapeutic interventions for
the treatment of AD has largely concentrated on the Ab-
part of the pathology, since it is most upstream of the
neurodegenerative cascade (for recent reviews see for
example [41, 42]). However, it has also become evident
that Ab has physiological functions and that the secretases,
which cleave APP, are involved in many biological pro-
cesses, which complicates to therapeutically interfere with
the amount or the processing of Ab. As a consequence, tau
and microtubules as prominent downstream targets of the
cascade came into focus. The finding that loss of tau in KO
animals has no drastic effect on brain development and
function [43, 44], further promoted the development of tau-
directed strategies since it could be expected that modu-
lation of the amount of tau would have fewer side effects. It
should however be taken into account that the functional
redundancy of neuronal microtubule-associated proteins
might limit the impact of tau depletion since changes in the
expression of MAP1A, MAP1B, and MAP2 have been
reported in tau KO animals [45]. In addition, muscle
weakness and some hyperactivity have been observed [46]
and the absence of functional tau may render the central
nervous system (CNS) more vulnerable to secondary
insults [47].
2 Rationale Behind the Development of Tau-
Directed Therapies
Tau proteins are microtubule-associated proteins (MAPs)
that are abundant in neurons of the central and peripheral
nervous system of vertebrates. Tau is enriched in the axon,
where it shows a proximo-distal gradient during
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development [48]. Human tau proteins are encoded by a
single gene on chromosome 17q21 that consists of 16
exons (Fig. 2, top). In the CNS, six tau isoforms are pro-
duced by alternative splicing of three exons (Fig. 2, red
boxes). Miss-splicing of tau, in particular an increase in the
formation of longer tau isoforms, can contribute to tauo-
pathies [49] and the tau isoform distribution can also be
modulated by the formation of stress granules [50].
Tau belongs to the major phosphoproteins in the brain
and PHF-tau is phosphorylated at several serine and thre-
onine residues (Fig. 2). Abnormally phosphorylated tau
was observed in selected subcortical areas long before its
presence in the cerebral cortex, which could indicate that
disease-like phosphorylation occurs already in early, pre-
clinical disease states [51]. In addition, tau is subject to
various other post-translational modifications including
O-glycosylation, ubiquitination, methylation and acetyla-
tion [52]. Interestingly, tau acetylation at Lys174 has
recently been identified as an early modification in brains
from patients with AD, which slowed down tau turnover in
a mouse model and promoted tau aggregation [53].
Furthermore, N- and C-terminal truncation of tau has been
observed, which might influence its interaction with
microtubules, aggregation into filaments and cellular
localisation [54, 55]. Proteolytic cleavage of tau could be
very relevant for disease development and progression
since it might generate neurotoxic fragments [56–59]
(Fig. 2).
Tau fits into the class of intrinsically disordered pro-
teins, which are able to interact with a large number of
partners, thereby serving as hubs in cellular protein-protein
interaction networks [60]. Several tau interaction partners,
which might be of functional importance, have been
identified in addition to microtubules. These include
membrane-associated proteins such as annexin A2, which
contributes to tau’s axonal localisation [61, 62], src-family
non-receptor tyrosine kinases such as fyn [63], which
might be involved in conferring Ab toxicity at the post-
synapse [64], and protein phosphatase 2A, which is the
primary tau phosphatase [65, 66].
Based on function and amino-acid composition, four
regions of tau can be distinguished (Fig. 2). The (1)
Fig. 2 Transcript variants and functional organisation of tau. The
exon structure of tau with official numbering is shown on top. The
often used conventional nomenclature according to Andreadis et al.
[138] is shown in brackets. Exons that are expressed in CNS tau are
indicated in dark grey (constitutively present) and red (alternatively
spliced). Exons, which are only present in the PNS form of tau are
indicated in light grey. The functional organisation of the longest
human CNS isoform (441 tau) is shown below. Phosphorylation sites
that have been identified in PHF-tau by mass spectrometry according
to [139] are indicated. Calpain and caspase-3 cleavage sites that have
been implicated in producing neurotoxic tau fragments are shown
according to [58, 140] (arrowheads). The repeat regions, which
constitute the basic microtubule interacting unit, are indicated as R1-
R4. CTR C-terminal region, MBR microtubule-binding region, MT
microtubule, PHFs paired helical filaments, PRR proline-rich region
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N-terminal projection region, which protrudes from the
microtubule surface when tau is bound to microtubules, (2)
the proline-rich region (PRR), (3) the microtubule-binding
region (MBR), (4) the C-terminal region (CTR). The
N-terminal region appears to serve as a spacer to keep
axonal microtubules apart and might also act as a linker to
membrane components such as annexin A2 [62, 67]. The
PRR is required for microtubule nucleation and harbours
also the fyn-interaction site [68, 69], and the CTR is
involved in regulating tau’s activity to induce microtubule
polymerisation and its interaction with the plasma mem-
brane [68, 70].
Tau’s dominant interaction partners are microtubules
and more than 80 % of tau is bound to microtubules in
neuronal processes at every time point [61, 71]. Binding of
tau to microtubules occurs through three or four imperfect
18-amino acid repeats (R1–R4) separated by linker
sequences of 13–14 amino acids. The repeats are located in
the MBR with a single repeat as the basic microtubule
interacting unit [72] (Fig. 2). In neuronal processes, tau
shows a very short interaction time with microtubules
(40 ms) and interacts via a ‘‘kiss and hop’’ mechanism
[73]. This mechanism provides an explanation why tau,
although at every time point mostly bound to microtubules,
does not interfere with axonal transport processes [74]. In
addition, it rationalises why tau can have multiple inter-
action partners in addition to microtubules and is present in
different cellular compartments. The MBR is also involved
in other interactions, e.g. binding of tau to actin filaments
and protein phosphatase 2A, and is required for tau
aggregation in PHFs [75].
Formation of tau aggregates has not only been observed
in AD but also in some other diseases, which are now
collectively designated as ‘‘tauopathies’’. Some tauopathies
but not AD [in particular cases of the autosomal dominant
neurodegenerative disorder Frontotemporal dementia and
Parkinsonism linked to chromosome 17 (FTDP-17)] are
caused by mutations in the tau gene [49]. Exonic FTDP-17
mutations in the tau gene are often used to model AD-like
tau pathology in animal models; however, tau’s involve-
ment in FTDP-17 cases might be mechanistically distinct
from non-mutated tau in AD and differs from the human
neuropathology [24, 76]. Past research has concentrated on
the effect of higher tau aggregates as the toxic species;
however, evidence indicates that, similar to Ab, oligomeric
tau rather than higher aggregates represent the toxic species
[77]. Such a view is also supported by the finding that
soluble hyperphosphorylation-mimicking tau gains toxic
properties in human model neurons, ex vivo cultures and
animal models [34, 35, 78].
Based on the biology of tau and its involvement in the
neurodegenerative process, several target mechanisms
could be envisioned. One aspect would be to address post-
translational modifications of tau by inhibiting kinases such
as GSK3b, promoting the activity of PP2A or affecting
acetylation. Such approaches are reviewed elsewhere [41]
and will not be discussed in this article since they are not
specifically directed to tau. A second target could be tau
aggregation. A third target could be the overall amount of
tau or individual pathologically modified tau species.
Only few compounds that are claimed to address tau or
the main target of tau, microtubules, have progressed for
clinical testing so far. One is TRx0237 (modified methy-
lene blue, Rember), a tau aggregation inhibitor, the others
are the microtubule stabilizer BMS-241027 (epothilone D)
and treatments, which might decrease the amount of tau
protein or phospho-tau (davunetide, sGC-1061, immuni-
sation approaches). They will be discussed in the following
section.
2.1 Inhibition of Tau Aggregation with TRx0237
TRx0237 (LMTXTM), chemical name methylthionium
chloride, is a modified version of the small-molecule drug
Rember (methylene blue), which decreases tau aggregation
among other activities. The parent compound, methylene
blue, has a long history and is used for treatment of malaria
and several other conditions (for a historical overview see
[79]). In 1996, methylene blue was reported to inhibit tau
aggregation in vitro by blocking the tau-tau binding inter-
action, which occurs through the MBR [80] (see Fig. 2). The
mechanism may involve cysteine oxidation of tau in the
MBR since methylene blue caused a respective oxidation
in vitro [81]. Thus, the rationale behind the application of
TRx0237 is that aggregate formation is the mechanism by
which tau becomes toxic and that inhibition of aggregation
might reduce the gain of toxicity (see Fig. 1).
In a phase II trial, treatment with methylene blue for
50 weeks resulted in improvement in cognitive function [as
determined by the Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog)] in both mild and moderate
AD subjects [82]. Positive effects were seen at
138 mg/day, while a higher dose (228 mg/day) was inef-
fective. The failure of dose response was hypothesised to
be due to differences in redox processing and absorption
[83]. This led to the synthesis of LMTXTM as a more
stable form for application in the reduced state [84].
LMTXTM inhibited tau aggregation in a cellular assay and
reduced tau aggregates and rescued learning impairment in
two tau-aggregation prone mouse models, which expressed
either a truncated tau fusion protein or a full-length tau
protein with FTDP-17 mutations [85]. Currently, LMTXTM
is tested in several studies in subjects with mild to mod-
erate AD and a behavioural variant of frontotemporal
dementia at concentrations of 100–300 mg/day. Top-line
data are expected to be reported in 2016.
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As discussed before, it is currently unclear, whether
higher tau aggregates or oligomeric tau forms represent the
toxic species. Currently it cannot be excluded that the
formation of higher tau aggregates (PHFs or NFTs) rep-
resents a rescue mechanism by which the cells aim to store
toxic, misfolded tau monomers or oligomers in a biologi-
cally more inert form. In such a scenario, approaches to
disassemble higher tau aggregates could even be contra-
productive since they would increase the amount of toxic
tau species. In any case, methylene blue and its modified
forms may act not primarily through their anti-aggregation
properties against tau filaments. In a transgenic mouse
model, methylene blue reduced Ab levels and improved
learning and memory by an increase in Ab clearance,
probably by increasing proteosome function [86]. In cell
models and organotypic brain slices, methylene blue
induced autophagy, suggesting this as a mechanism of
reducing tau levels [87]. Thus, the drug might have ame-
liorated AD pathology by acting upstream of tau pathology
at the level of Ab or by increasing clearance of misfolded
proteins. In Caenorhabditis elegans and zebrafish, methy-
lene blue suppressed toxicity in genetic models of Amy-
otrophic lateral sclerosis (ALS), probably by a mechanism
that involved a reduction of oxidative stress [88]. Methy-
lene blue also reduced protein aggregation in a zebrafish
model of Huntington’s disease, but it did not affect phos-
phorylation or inhibit toxicity, which was induced by
transgenic expression of a tau mutant [89]. Thus, the data
support that methylene blue is a pleiotropic molecule,
which has various effects that could be therapeutically
useful, but that does not classify methylene blue as a
specific tau-aggregation inhibitor.
2.2 Microtubule Stabilisation with BMS-241027
BMS-241027, also known as Epothilone D, is a small-
molecule microtubule stabiliser. It belongs to the family of
epothilones, which are synthetic taxol-derived compounds
and comprise a relatively large class of MT-stabilising
agents [90]. In contrast to paclitaxel (taxol) and most other
taxanes, Epothilone D and selected congeners are brain
penetrant [91]. Epothilones may have neuroprotective
activity and it has been reported that Epothilone D reduces
transport deficits and improves cognition in different tau
transgenic mice by stabilising axonal MTs [92–94]. In a
tauopathy mouse model, microtubule hyper-dynamicity
could be reduced with low doses of BMS-241027 to
baseline levels [92]. Recent data also show that EpoB or D
promote axon regeneration after transection injury in vitro
and spinal cord injury [95, 96]. However, dose-dependent
neurotoxic effects have also been noted both with certain
epothilones as well as other MT-binding agents [97, 98].
The rationale behind the use of BMS-241027 is that
tauopathies such as AD exhibit disturbed microtubule
dynamics and that modulation of microtubule stability may
be beneficial to prevent neurodegeneration (see Fig. 1).
In a phase I study, the safety, tolerability and the effect
of BMS-241027 on CSF biomarkers in subjects with mild
AD was tested at 0.003, 0.01 and 0.03 mg/kg of infused
drug for nine weeks compared to a placebo by Bristol-
Myers Squibb. The effect of the drug on changes in CSF
concentrations of an N-terminal and a mid-domain tau
fragment, results of connectivity MRI, performance in
cognitive tests and various pharmacodynamic measures
were assessed. The study ended in 2013 and evaluation of
BMS-241027 for AD was discontinued.
Changes in microtubule dynamics are a common end-
point in many neurodegenerative diseases [99] and stabil-
isation of hyperdynamic microtubules is neuroprotective in
a mouse model of ALS [100] and normalised transport
deficits [101]. However, changes of microtubule dynamics
in AD appear to be more indirect than originally assumed
since neither overexpression nor knockout of tau affects
transport processes [74] and no major changes in micro-
tubule stability were observed after acute tau knockout in
cells or in tau KO mice [43, 102]. Thus, the classical ‘‘loss
of function’’ hypothesis, which states that inactivation of
tau, e.g. by disease-like hyperphosphorylation or aggrega-
tion, appears questionable. Instead, tau may rather disturb
microtubule dynamics by a ‘‘gain of toxic function’’
mechanism. Furthermore, evidence exists that Ab can also
induce changes in microtubule dynamics independent of
tau [103]. Taken together, modulating microtubule
dynamics can be a valuable tool since disturbance of
microtubule dynamics is involved in several aspects of the
neurodegenerative triad (see Fig. 1); however, tau may
only be partially and probably more indirectly involved. In
addition, while stabilisation of microtubules may be ben-
eficial at disease conditions, it may be toxic at healthy
conditions. Thus, the dose of the drug and the state of the
patients would need to be tightly controlled in order to
yield positive effects by microtubule modulating agents,
and chronic treatment at low concentrations for much
longer times than the nine weeks in the Bristol-Myers
Squibb study might be required for beneficial effects.
2.3 Decrease of Tau Hyperphosphorylation
and Neuroprotection with Davunetide
NAP (NAPVSIPQ; generic name: davunetide) is a peptide
derived from activity-dependent neuroprotective protein
(ADNP). NAP has been connected to the treatment of
tauopathies by the observation that ADNP-deficiency leads
to tauopathy, which is inhibited by davunetide [104, 105];
however, direct experimental evidence for a relation
between tau and NAP remained weak. Nevertheless, NAP
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has been repeatedly claimed as representing a tau-targeting
drug [106]. ADNP is involved in brain development and
harbours neuroprotective activities in a sequence motif,
which corresponds to NAP. In an AD mouse model, ADNP
expression was increased compared to control animals
suggesting an involvement in the disease [107]. It has been
reported that davunetide stabilises microtubules and redu-
ces hyperphosphorylated tau levels [108]. In a-synuclein
overexpressing mice as a model for Parkinson’s disease
(PD) it reduced tau hyperphosphorylation and improved
behavioural deficits [109] and in an ALS mouse model it
protected against impairments in axonal transport [110].
The rationale behind the application of davunetide is that
patients with tauopathies exhibit tau hyperphosphorylation,
disturbed microtubule dynamics and cell death and that
reduction of tau hyperphosphorylation, stabilisation of
microtubules and neuroprotective effects may be beneficial
to prevent disease progression (see Fig. 1).
A phase II study in patients with mild cognitive
impairment showed that intranasally administered
davunetide is safe, well tolerated, and has a positive effect
on cognition [111]. However, davunetide failed to show
efficacy for treatment of the tauopathy progressive
supranuclear palsy (PSP) in a phase II trial [112]. The
participants received either 30 mg of intranasal davunetide
or placebo twice a day for one year. The company that
conducted the study (AllonTherapeutics Incorporated)
announced that there are no further plans with the drug.
Davunetide (and probably also ADNP) appears to have
pleiotropic functions, which is also evident from the find-
ing that it is involved in immune-regulation [113]. Such
drugs may be helpful at early disease stages, when tau
pathology is not yet fully developed to support physio-
logical microtubule dynamics and neuronal survival. Fur-
thermore, also immunomodulatory activities could be
therapeutically helpful since inflammation is a risk factor
for AD (see above). Using a pleiotropic drug such as
davunetide in patients with mild cognitive impairment
appears to be more appropriate than a trial in a pure
tauopathy and also suggests that davunetide does not
classify as a primarily tau-directed target.
2.4 Lowering the Level of Tau with sGC-1061
sGC-1061 belongs to a class of compounds designated as
‘‘nomethiazoles’’, which have been designed to deliver
exogenous nitric oxide (NO) to the CNS as a NO mimetic.
With respect to its mechanism of action, sGC-1061 has
been claimed—among other activities—to be a tau protein
inhibitor. However, experimental evidence is limited to a
poster presentation, where sGC-1061 was reported to sig-
nificantly lower the amount of Ab and tau protein in mouse
models (Thatcher et al. [114]). Signal transduction by the
NO/soluble guanylyl cyclase/cGMP system is important
for modulating synaptic transmission and plasticity and
may have pro-survival activity against neurotoxic insults
[115]. Depression of NO-signalling has been observed in
AD [116]. In a rat model with experimentally damaged
cholinergic neurons, NO mimetics were able to reverse
cognitive deficits [117], restored synaptic alterations in
slice cultures from mouse models of AD, and displayed
neuroprotective activity [118]. The rationale behind the use
of sGC-1061 with respect to the tau pathology is that
lowering the amount of tau could be beneficial with respect
to the tau-dependent aspects of the neurodegenerative triad
(see Fig. 1).
sGC-1061 as a potential drug is developed by sGC
Pharma Inc. and is in phase I evaluation in AD, but no
further information is available to date.
To decrease the level of tau by therapeutic intervention
could be a useful approach to limit a gain-of-toxicity of tau
during disease progression. However, also sGC-1061 (as
well as NO signalling) has pleiotropic effects and the
available data do not support a classification as a tau-di-
rected drug. In any case, it will be very difficult to evaluate,
whether potential beneficial effects of sGC-1061 are due to
changes in the level of tau, caused by decreased levels of
Ab, or due to other neuroprotective activities. This does not
exclude that sGC-1061—similar to davunetide or
TRx0237—could be useful to delay the onset of symptoms
in early phases of AD, but probably not due to a direct
effect on tau pathology.
2.5 Lowering the Level of Phospho-Tau by Active
or Passive Immunisation
Several studies using active immunisation against phospho-
tau peptides have raised the possibility of modulating tau
pathology in tauopathy or AD mouse models [119–121]. It
has also been demonstrated that the antibodies passed the
blood-brain barrier and were present in the brain [119]. In
addition, also passive immunisation by peripheral admin-
istration of an antibody against a phospho-tau epitope, a
conformation-dependent antibody recognising pathological
tau conformation, an antibody against tau oligomers, or
antibodies targeting tau’s N-terminus reduced tau pathol-
ogy and disease progression in tauopathy mouse models
[122–125]. Passive immunisation with phospho-tau-speci-
fic antibodies also resulted in a significant decline in brain
and CSF phospho-tau levels [126]. In addition, tau-targeted
immunisation also reduced NFT pathology after onset of
tangle formation in a tauopathy mouse model [127].
However, it should be taken into consideration that active
or passive immunisations against endogenous proteins
carry the risk of inducing autoimmunity or other compli-
cations [128]. In fact, Mably et al. [129] reported that
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passive immunisation against tau in APP transgenic mice
was not only inactive in recovering memory defects but
even increased mortality of the animals. The rationale
behind the application of immunisation against pathologic
tau variants is that only misphosphorylated, misfolded or
oligomeric tau is removed, thus reducing the potential gain
of toxicity of modified tau protein (see Fig. 1).
A phase I safety study was performed by Axon Neuro-
science in patients with mild-to-moderate AD using a
candidate therapeutic vaccine, AADvac1. The vaccine’s
antigenic determinant is a synthetic peptide derived from
tau and encompasses a region that plays a regulatory role
for pathological tau-tau interactions. Interestingly, the
respective tau peptide sequence (294KDNIKHVPGGGS305;
[130]) represents the 2nd microtubule binding repeat,
which is alternatively spliced and only present in 4-repeat
tau isoforms (see Fig. 2). The tau sequence is coupled to
keyhole limpet haemocyanin and uses aluminium hydrox-
ide as an adjuvant for active immunisation. Patients
received 3–6 immunisation doses. An 18-months safety
follow-up study is currently running and the estimated
primary completion date will be May 2017. A study using a
rat model confirmed that the vaccine discriminates between
pathological and physiological tau, reduces tau oligomers
and decreases tau pathology [131]. In another phase I study
by AC Immune SA, Janssen, a liposome-based vaccine
(ACI-35) with phosphorylated synthetic tau fragments is
tested in people with mild to moderate AD. The vaccine
has previously been reported to be active and safe in a
mouse tauopathy model [132].
It appears surprising that immunisation against a protein
that exerts its neurotoxic activity within cells is effective in
reducing tau pathology and cognitive decline. However, it
has been known for some time that tau is also present in the
CSF and that the amount of both total tau and phospho-tau
increases in the CSF of AD patients [133]. Within the CSF,
tau appears to be mainly in the form of fragments [134].
Tau may leak from neurons and antibody treatment could
increase tau release by producing an extracellular sink so
that the concentrations of intracellular tau decrease.
Extracellular misfolded or oligomeric tau fragments may
also exert toxic activity, which is decreased by the presence
of neutralising antibodies. In support of a toxic action of
extracellular tau, it has been reported that tau oligomers
can be internalised by iPS cell-derived human neurons and
cause neurodegeneration by inducing accumulation of
endogenous tau [135]. Alternatively, antibodies may be
taken up by cells. In fact, internalisation of monoclonal tau-
targeting antibodies by neurons has been demonstrated,
where they colocalised with pathological tau in brain slices
[136]. Recently, it has also been shown that therapeutic
antibodies promote uptake of tau fibrils into microglia via
Fc receptors with a preference for larger oligomers,
suggesting a mechanism how tau clearance in the brain is
promoted by antibody treatment [137].
3 Conclusions
Tau has a central role in the downstream cascade that
mediates the Ab-induced neurodegenerative triad during
the progression of AD. As shown in Fig. 1, oligomeric or
misfolded tau protein can gain toxic activity and kill neu-
rons. In addition, tau can induce dendritic simplification by
a mechanism that involves a disturbance of microtubule
dynamics. Thus, tau-directed strategies might be useful to
ameliorate neurodegenerative changes downstream of the
action of Ab.
However, most of the drugs that are currently in clinical
trials do not qualify as primarily tau-targeting agents since
they have pleiotropic activities, and evidence that they
exhibit their main biological function on tau is weak.
Addressing the main tau target, microtubules, also
appears to be attractive. However, changes in microtubule
dynamics are a common endpoint in many neurodegener-
ative diseases and might more indirectly relate to tau
pathology than previously assumed. Ab can induce chan-
ges in microtubule dynamics independent of tau, and tau’s
major function appears not to be to stabilise microtubules.
Modulating microtubule dynamics can be a valuable gen-
eral approach to stabilise neurons in various neurodegen-
erative disorders; however, microtubule over-stabilisation
may also have adverse effects at healthy conditions since
microtubule dynamicity is involved in many aspects of the
life of a neuron.
Lowering the level of tau and potentially toxic tau
species may currently be the most promising approach for a
tau-directed therapy. Brain and cell penetrating small
molecules that decrease tau expression, stabilise physio-
logical tau conformation, prevent the formation of poten-
tially toxic tau fragments or inhibit the formation of
oligomeric tau (without interfering with higher tau aggre-
gates) could provide an effective strategy to specifically
block aspects of the neurodegenerative triad by a tau-tar-
geting approach.
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